期刊文献+

Inhibitory action of docetaxel on the proliferation of HeLa and SiHa cells

Inhibitory action of docetaxel on the proliferation of HeLa and SiHa cells
下载PDF
导出
摘要 Objective To study the inhibitory action of docetaxel(DOC)on the proliferation of HeLa and SiHa cells.Methods Cell morphological changes were observed with inverted phase contrast microscope.MTT was adopted to test and calculate the cell inhibition ratio.Flow cytometry was used to detect cell cycle.Results DOC had an obvious concentration-dependent inhibitory effect on the proliferation of both HeLa and SiHa cells.The inhibition ratio of DOC on SiHa was significantly higher than that on HeLa(P<0.05).DOC blocked HeLa at G2/M phase.Under the effect of DOC,the cell cycle of SiHa was not changed much.Conclusion DOC has an obvious inhibitory action on both HeLa and SiHa cells,which shows a promising prospect of DOC in clinical treatment of cervical cancer. Objective To study the inhibitory action of docetaxel(DOC)on the proliferation of HeLa and SiHa cells.Methods Cell morphological changes were observed with inverted phase contrast microscope.MTT was adopted to test and calculate the cell inhibition ratio.Flow cytometry was used to detect cell cycle.Results DOC had an obvious concentration-dependent inhibitory effect on the proliferation of both HeLa and SiHa cells.The inhibition ratio of DOC on SiHa was significantly higher than that on HeLa(P<0.05).DOC blocked HeLa at G2/M phase.Under the effect of DOC,the cell cycle of SiHa was not changed much.Conclusion DOC has an obvious inhibitory action on both HeLa and SiHa cells,which shows a promising prospect of DOC in clinical treatment of cervical cancer.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2010年第4期260-264,共5页 药物分析学报(英文版)
关键词 DOCETAXEL chemotherapy cervical cancer HELA SIHA PROLIFERATION docetaxel chemotherapy cervical cancer HeLa SiHa proliferation
  • 相关文献

参考文献8

  • 1朱青山,刘基巍.多西他赛联合顺铂治疗蒽环类化疗失败乳腺癌的临床研究[J].中国现代医学杂志,2006,16(18):2828-2829. 被引量:2
  • 2魏爱英,张庆柱,张捷.多西他赛诱导乳腺癌Bcap37细胞凋亡作用的研究[J].中华肿瘤防治杂志,2006,13(18):1384-1386. 被引量:10
  • 3Ronald Schimming,Kathryn A. Mason,Nancy Hunter,Michael Weil,Kazushi Kishi,L. Milas.Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel[J],1999.
  • 4Zhang XL.Recent development of research on antineoplastic taxotere preparationProg Phar m Sci Chin,2006.
  • 5Ma JL,Li HZ,Xu YP.Clinical analysis and evaluation of do-cetaxelChina Prescription Drug,2008.
  • 6Guan WM,Fan Y,Guo XL, et al.Inhibition of Docetaxel on Proliferation of Colon Cancer LoVo Cell LineFudan Univ J Med Sci,2005.
  • 7Sardi JE,Boixadera MA,Sardi JJ.Neoadjuvant chemotherapy in cervical cancer: a new trendCurrent Opinion,2005.
  • 8Lopez M F,Berggren K,Chernokalskaya E,et al.A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profilingElectrophoresis,2000.

二级参考文献12

  • 1刘龙,刘璐,童冠圣,封国生,高宏,高文,李澄,刘志勇.^(32)P-磷酸铬体外诱导人非小细胞肺癌A549细胞凋亡[J].中华放射医学与防护杂志,2004,24(3):233-236. 被引量:2
  • 2郑天郢,王永刚,张昕,王秀问,黎莉,于学军.两组解救方案治疗蒽环类耐药的晚期乳腺癌疗效观察[J].中国肿瘤临床,2004,31(16):943-945. 被引量:2
  • 3宋谦,李露嘉,侯晓伟,夏放.周剂量泰索帝联合铂类方案治疗晚期非小细胞肺癌[J].中国现代医学杂志,2004,14(17):136-137. 被引量:4
  • 4Tabernero J, Climent M A, Lluch A, et al. Amulticentre, randomised phase II study of weekly or S-weekly docetaxel in patients with metastatic breast cancer[J]. Ann Oncol, 2004, 15(9): 1358-1365.
  • 5Ishikawa T, Shimizu S, Inaba M, et al. A Multieenter phase Ⅱ study of docetaxel 60 mg/m^2 first-line chemotherapy in patients with advanced or recurrent nreast cancer[J]. Breast Cancer,2004, 11(4): 374-379.
  • 6Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase Ⅱ multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer[J]. Br J Cancer,2004, 91(8): 1466-1471.
  • 7Mavroudis D, Malamos N, Polyzos A, et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenterphase II study[J]. Oncology,2004, 67(3-4): 250-256.
  • 8Gomez-Bernal A, Cruz J J, Olaverri A, et al. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer[J]. Anticancer Drugs, 2005,16 (1) : 77 - 82.
  • 9Park S H, Cho E K, Bang S M, et al. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment[J]. BMC Cancer,2005,22(5):21-21.
  • 10Wolff A C, Davidson N E. Primary systemic therapy in operable breast cancer[J]. J Clin Oncol,2000,18(7) .1558-1569.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部